Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

Journal of Neuroinflammation

Volumn 1, Issue , 2004, Pages

  Sánchez Pernaute, Rosario ^a,b   Ferree, Andrew ^a,b   Cooper, Oliver ^a,b   Yu, Meixiang ^a,c   Brownell, Anna Liisa ^a,c   Isacson, Ole ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; OXIDOPAMINE; TRACER; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN PROTECTION; CELL ACTIVATION; CELL COUNT; CELL DENSITY; CELL LOSS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME INHIBITION; IN VIVO STUDY; MICROGLIA; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; RAT;

EID: 4344645719     PISSN: 17422094     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-2094-1-6     Document Type: Article

References (67)

1. Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
3. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP: The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:214-228.
4. McGeer PL, Schwab C, Parent A, Doudet D: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599-604.
5. Drachman DB, Rothstein JD: Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000, 48:792-795.
6. Hara K, Kong DL, Sharp FR, Weinstein PR: Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats. Neurosci Lett 1998, 256:53-56.
7. Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA, Isakson PC, Chen J, Graham SH: Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A 1998, 95:10954-10959.
8. Teismann P, Ferger B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-174.
9. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
10. Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001, 21:6480-6491.
11. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297.
12. Castano A, Herrera AJ, Cano J, Machado A: Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998, 70:1584-1592.
13. Shibata H, Katsuki H, Nishiwaki M, Kume T, Kaneko S, Akaike A: Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin. J Neurochem 2003, 86:1201-1212.
14. Hirsch EC, Hunot S, Damier P, Faucheux B: Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998, 44(3 Suppl 1):S115-20.
15. Hunot S, Hirsch EC: Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003, 53 Suppl 3:S49-58; discussion S58-60.
16. Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC: FADD: A link between TNF family receptors and caspases in Parkinson's disease. Neurology 2002, 58:308-310.
17. Knott C, Stern G, Wilkin GP: Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
18. Nagatsu T, Mogi M, Ichinose H, Togari A: Cytokines in Parkinson's disease. J Neural Transm Suppl 2000:143-151.
19. Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000:277-290.
20. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. Faseb J 2002, 16:1474-1476.
21. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kaji R, Kuno S: Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 2001, 311:1-4.
22. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60:1059-1064.
23. Shannon KM, Penn RD, Kroin JS, Adler CH, Janko KA, York M, Cox SJ: Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients. Neurology 1998, 50:434-438.
24. Ono K, Han J: The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1-13.
25. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
26. Sauer H, Oertel WH: Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
27. Oiwa Y, Sanchez-Pernaute R, Harvey-White J, Bankiewicz KS: Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J Neurosurg 2003, 98:136-144.
28. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O: Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15:991-998.
29. Bjorklund A, Rosenblad C, Winkler C, Kirik D: Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiology of Disease 1997, 4:186-200.
30. Costantini LC, Isacson O: Neuroimmunophilin ligand enhances neurite outgrowth and effect of fetal dopamine transplants. Neuroscience 2000, 100:515-520.
31. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press; 1986.
32. Brownell A-L, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O: Combined PET/MRS studies of the brain reveal dynamic and long-term physiological changes in a Parkinson's disease primate model. Nature Med 1998, 4:1308-1312.
33. Hantraye P., Brownell, A.-L., Elmaleh, D., Spealman, R.D., Wullner, U., Brownell, G.L., Isacson, O.: Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 1992, 3:265-268.
34. Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T, Duncan JS: [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology 1999, 53:2199-2203.
35. Brownell AL, Livni E, Galpern W, Isacson O: In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Annals of Neurology 1998, 43:387-390.
36. Camsonne R, Crouzel C, Comar D, Maziere M, Prenant C, Sastre J, Moulin MA, Syrota A: Synthesis of N-(11-C) Methyl, N-(Methyl-1 Propyl), (Chloro-2 Phenyl)-1 Isoquinoleine Carboxamide-3 (PK 11195): A new ligand for peripheral benzodiazepine receptors. Journal of Labelled Compounds and Radiopharmaceuticals 1984, XXI:985-991.
37. Correia J., Burnham, C., Kaufman, D., Fischman, A.: Development of a small animal PET imaging device with resolution approaching 1mm. IEEE Trans Nucl Sci 1999, 46:631-635.
38. Cicchetti F, Costantini L, Belizaire R, Burton W, Isacson O, Fodor W: Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain. Exp Neurol 2002, 177:376-384.
39. Isacson O: On Neuronal Health. Trends Neurosci 1993, 16:306-308.
40. Hartmann A, Hunot S, Hirsch EC: Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol 2003, 184:561-564.
41. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH: Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18:2731-2742.
42. Schiefer J, Kampe K, Dodt HU, Zieglgansberger W, Kreutzberg GW: Microglial motility in the rat facial nucleus following peripheral axotomy. J Neurocytol 1999, 28:439-453.
43. Isacson O, Brundin P, Gage FH, Bjorklund A: Neural grafting in a rat model of Huntington's disease: Progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 1985, 16:799-817.
44. Volpe BT, Wildmann J, Altar CA: Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 1998, 83:741-748.
45. Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC: Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 1999, 6:1936-1951.
46. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O: Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in rat. Proc Nat Acad Sci U S A 1994, 91:5104-5108.
47. Cunningham LA, Su C: Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 2002, 174:230-242.
48. Isacson O, Fischer W, Wictorin K, Dawbarn D, Bjorklund A: Astroglial response in the excitotoxically lesioned neostriatum and its projection areas in the rat. Neuroscience 1987, 20:1043-1056.
49. Mladenovic A, Perovic M, Raicevic N, Kanazir S, Rakic L, Ruzdijic S: 6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res 2004, 996:237-245.
50. Adams FS, LaRosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A, Freed CR, Prasad KN: Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochemical Research 1996, 21:619-627.
51. Yamamoto S, Yamamoto K, Kurobe H, Yamashita R, Yamaguchi H, Ueda N: Transcriptional regulation of fatty acid cyclooxygenases-1 and -2. Int J Tissue React 1998, 20:17-22.
52. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J: A p38 MAP kinase inhibitor regulates stability of interleukin-1- induced cyclooxygenase-2 mRNA. FEBS Lett 1998, 439:75-80.
53. Monick MM, Robeff PK, Butler NS, Flaherty DM, Carter AB, Peterson MW, Hunninghake GW: Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem 2002, 277:32992-33000.
54. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC: Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002, 16:2103-2112.
55. Minghetti L, Levi G: Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99-125.
56. Stokes AH, Hastings TG, Vrana KE: Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665.
57. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G: Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. Faseb J 2001, 15:1622-1624.
58. Tegeder I, Niederberger E, Vetter G, Brautigam L, Geisslinger G: Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J Neurochem 2001, 79:777-786.
59. Nogawa S, Zhang F, Ross ME, Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746-2755.
60. Kunz T, Oliw EH: The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 2001, 13:569-575.
61. Scali C, Giovannini MG, Prosperi C, Bellucci A, Pepeu G, Casamenti F: The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 2003, 117:909-919.
62. Hastings TG: Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
63. Conway KA, Rochet JC, Bieganski RM, Lansbury P. T., Jr.: Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
64. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003, 100:5473-5478.
65. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA: JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004, 101:665-670.
66. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH: Age-related microglial activation in 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-294.
67. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.